ClinicalTrials.gg
RecruitingNCT06097091Updated Nov 20, 2024

Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia

An interventional study of Self-management education and pain neuroscience education in Fibromyalgia, sponsored by Taipei Medical University. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Taipei Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Fibromyalgia with a site in Taiwan — 4 open to participants now, 4 under way, none of them phase 3. Fibromyalgia · Taiwan.

Planned enrollment
7th of 11
98 · median 105
Started
2023
the only one that year
No phase
6 of 12
3 open now
Registered
11th of 12
by date
Lead sponsor
5 of 12
Taipei Medical University

Among the 12 studies in Fibromyalgia with a site in Taiwan, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 6 with no phase, and was the 11th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

4 of the 12 studies in Fibromyalgia with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Fibromyalgia with a site in Taiwan, or all of them as a file.
02

Study summary

This randomized controlled trials study aims, first, to determine the effectiveness of a nurse-led PNE program designed by a multidisciplinary team, compared with an active control group on pain intensity, fibromyalgia (FM) severity, pain catastrophizing, and cognitive performance in patients with FM. Second, to determine the mediator role of pain catastrophizing in the effects of PNE on outcomes of interest. Third, to explore PNE-induced changes to the brain circuitry using QEEG in patients with FM.

Read the detailed description

This is a parallel-group, randomized controlled trial (RCT). 98 participants who meet the 2016 American College of Rheumatology diagnostic criteria for FM will be enrolled.

Eligible participants who complete the baseline measurements will be randomly allocated to a PNE group (N = 49) and a self-management education group (N = 49).

Primary outcomes include pain severity determined using the Brief Pain Inventory-Short Form (BPI-SF) and FM severity assessed using the Fibromyalgia Impact Questionnaire-Revised (FIQR).

Secondary outcomes, including pain catastrophizing and sustained attention, will examine using the Pain Catastrophizing Scale (PCS), the Psychomotor Vigilance Test (PVT), and QEEG, respectively.

All outcomes will be measured at 3 different time points: (T0: baseline; T1: immediately after the 6-week intervention period; and T2: 3 months after the intervention period).

Implications:

This will be the first-ever RCT to examine the effectiveness of a Chinese-language PNE program and the first study to determine the brain changes after PNE using QEEG in patients with FM. Once the effectiveness of the PNE and its brain mechanisms are supported by evidence from this trial, it will become a game changer in the management of the FM population. If an evidence-based PNE platform based on the patented training course is subsequently developed, the product will have great potential for commercialization.

03

Conditions studied

  • Fibromyalgia

Keywords

  • fibromyalgia
  • cognitive function
  • disease severity
  • pain catastrophizing
  • pain neuroscience education
  • pain severity
  • quantitative electroencephalography
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must read and understand Chinese language.
  • According to the 2016 ACR diagnostic criteria, participants' PDS scores more than or equal to 13 points

Exclusion criteria

Exclusion Criteria:

  • Subjects who have medical history of traumatic brain injury or neurological disorder.
  • Subjects who have present psychopathologic disorder.
  • Subjects who are cancer.
  • Subjects who are pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
98 participants (estimated)

Study arms

  • Active comparator
    Self-Management Education

    Participants in the control group will receive an SME via weekly video calls over 6 weeks.

    Other: Self-management education

  • Experimental
    Pain Neuroscience Education

    Participants in the experimental group will receive a 6-week PNE program.

    Behavioral: pain neuroscience education

Interventions

  • OtherSelf-management education

    A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).

  • Behavioralpain neuroscience education

    Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, "Explain Pain" by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content.

06

What researchers measure

Primary outcomes

  1. the Brief Pain Inventory-Short Form (BPI-SF)

    The BPI-SF evaluates pain in different contexts: worst pain, least pain, average pain, and current pain, rated on a 0-10 scale.

    Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.

  2. the Fibromyalgia Impact Questionnaire Revised (FIQR)

    The FIQR includes 21 questions involving 3 domains: physical function, overall effect of fibromyalgia, and fibromyalgia symptoms (pain, fatigue, unrefreshing sleep, stiffness, anxiety, depression, tenderness to touch, memory, balance, and environmental sensitivity).

    Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.

Secondary outcomes

  1. Pain Catastrophizing Scale(PCS)

    The PCS is a self-reported questionnaire consisting of 13 items that assess negative emotional and cognitive processes (e.g., helplessness, rumination, pessimism, and magnification of symptoms).

    Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.

  2. Psychomotor Vigilance Test (PVT)

    The standard 3-minute PVT will be used in this study to assess sustained or vigilant attention. The PVT is performed by recording the response time to visual stimuli, occurring at random inter stimulus intervals.

    Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.

Other outcomes

  1. Quantitative electroencephalography

    Resting-state EEG measurements with eyes closed will be taken for 10 min using the BrainMaster Discovery 24 EEG device. The participants will be seated with their eyes closed for 20 min before the measurements to achieve this stable/resting state. Five minutes of artifact-free EEG will be used in this study.

    Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Feb 2026, 29 months after the start.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 29 months is above that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 24, 2023
StartActual
Sep 6, 2023
Primary completionEst.
Feb 28, 2026
CompletionEst.
Jul 31, 2026
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06097091
Collaborators
Ministry of Science and Technology, Taiwan
Responsible party
Pei-Shan, Tsai (Principal Investigator, Taipei Medical University) — Principal investigator
First posted
Oct 24, 2023
Start date
Sep 6, 2023
Primary completion
Feb 28, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Nov 20, 2024

Study contacts

Pei-Shan Tsai, PhD
Contact
ptsai@tmu.edu.tw
+88627361661 ext. 6321
Pei-Shan Tsai, PhD
study chair · Taipei Medical University, Taiwan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion